Revenue from pharma tests, enterprise sales, and other customers in the range of $15 to $16 million; Revenue from population sequencing is expected to be zero due to completion of the prior VA MVP task order
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter